Growth Hormone Market Size By Product (Powder, Solvent), By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader-Willi Syndrome), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy,

Growth Hormone Market Size By Product (Powder, Solvent), By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader-Willi Syndrome), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Medstores), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027

The growth hormone market is projected to exhibit significant growth by 2027 due to the rising incidents of hormonal disorders in the global population and increasing regulatory approvals for growth hormone therapy.

Recent studies have found that contracting the COVID-19 infection during pregnancy can result in higher rates of preterm delivery, with around 15.5% of cases of small for gestational age (SGA). In some cases, infants with SGA may also develop a transient bullous eruption.

Moreover, another research found evidence suggesting that there is an increased risk of the SARS-CoV-2 infection with worse prognosis in male geriatric population with obesity and insufficient growth hormone (GH) secretion.

Thus, the increasing use of growth hormone therapy for the treatment of small for gestational age and other disorders is expected to boost market growth in the assessment period.

The growth hormone market has been categorized based on product, application, distribution channel, and region. Based on product, the solvent sub-segment is projected to exhibit a CAGR of over 8% through the analysis period owing to increasing distribution of drugs across the world.

On the basis of application, the market has been segmented into growth hormone deficiency, small for gestational age, turner syndrome, Prader–Willi syndrome, idiopathic short stature, and others.

The small for gestational age sub-segment had a market valuation of over USD 214 million in 2020 owing to increased usage of hormonal therapy for the disease.

Increasing use of growth hormone therapy for Prader–Willi syndrome (PWS) treatment is expected to fuel segmental growth in the coming years.

Recent studies have found that growth hormone therapy, which is a common treatment method for PWS is considered a safe and efficient for increasing lean muscle mass in children diagnosed with the syndrome and reducing body fat in adults suffering from PWS.

In terms of distribution channel, the hospital pharmacy sub-segment held more than 55% market share in 2020, owing to high volume of hospital visits and higher prescription rate.

In the regional scenario, Latin America is projected to witness a CAGR of over 6% during the forecast period, driven by increasing awareness regarding growth disorders and their treatment options.

Recently, a clinical stage biopharmaceutical firm, Saniona, announced a partnership with the Foundation for Prader–Willi Research (FPWR) to increase awareness about Phase 2b clinical trial of Tesomet, an investigational fixed-dose combination therapy of metoprolol and tesofensine, by Saniona, a treatment for PWS.

The leading companies in the sector include Pfizer, Ipsen, Merck, Genentech, Ferring Pharmaceuticals, Eli Lilly, and Novo Nordisk.

Earlier this month, Merck KGaA inked an agreement with PRA Health Sciences to merge the CRO’s remote patient monitoring platform and with its HGH (human growth hormone) treatment system.

The PRA platform is intended to back Merck’s HGH treatment, including easypod Connect, a platform for endocrinologists, and growlink, which is an application for patients prescribed along with Merck’s HGH treatment called Saizen (somatropun) to review injection history, monitor patient adherence to treatment, and share information about patients’ treatment progress.